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A B S T R A CT  
The global expansion of competent Dengue vectors in tropical and sub-tropical areas, and the favorable 
conditions for disease transmission demonstrates a critical public health challenge ahead. This review 
provides an insight into some key underlying gaps while attempting to suggest alternatives towards the 
containment and hence eradication of Dengue. The non-existence of an efficient vaccine against all 
DENV serotypes and the rapid global emergence of COVID-19, are undermining the complexities of 
vaccine development and disrupting global health efforts for the management of Dengue respectively. 
The development of sustainable DENV control programs now requires a multifaceted approach 
involving the integration of the recently developed multi-platforms application in entomological 
surveillance, community awareness, modelling, vaccination, vector control, and also ensuring that 
Dengue control efforts are not hampered or neglected during COVID-19 pandemic. This approach 
requires active collaboration and communication of scientists from various disciplines, economic 
support from funding agencies and institutions as well as support from the communities, governments 
and public health organizations. 
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1 Dengue and Dengue Virus 
Dengue fever, also commonly known as Dengue, 
is a mosquito-borne arboviral infection that has 
become the most rapidly expanding mosquito-
borne infectious disease on Earth, surpassing 
malaria [1]–[4]. Over the past few decades, the 
number of people infected with Dengue fever has 
risen exponentially reaching over 100 million 
people per annum with 22,000 deaths and placing 
almost 2.5 billion people at risk [2], [4], [5]. This 
expansion has been attributed to increased 
urbanization, global travel and commerce, and 
paucity of mosquito control programs [5]. 
Dengue fever or Dengue is caused by an infection 
with Dengue virus [2]. Dengue virus (DENV) is 
a mosquito-transmitted single-stranded, positive-
sense RNA virus that is a member of the genus 
Flavivirus and cycles in nature between its 
mosquito vectors and humans [5]. It comprises 
ten proteins; three proteins, capsid (C), 
membrane (M), and envelope (E), which play a 
structural role with seven proteins identified as 
non-structural but direct DENV replication [2]. 
Four distinct serotypes: DENV-1, DENV-2, 
DENV-3 and DENV-4 circulate in tropical and 
sub-tropical regions of the globe with each 
capable of causing severe disease and are 
transmitted via Aedes mosquitoes [2], [5]. DENV 
serotypes differ from one another by 25%–40% 
at the amino acid level and are separated further 
into genotypes that vary by up to 3% [5]. 
Clinically, Dengue patients tend to exhibit: 
extreme fatigue; sudden fever (from 3-7 days), 
headache, joint, muscle, and back pain; vomiting 
and diarrhea, appetite loss; skin rash along with 
minor bleeding [2]. There is no effective 
treatment for Dengue fever other than 
supportive care especially for severe cases, also 
called Dengue Hemorrhagic Fever (DHF) and 
Dengue shock syndrome [4]. 
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2 Historical Background 
The word “dengue” is derived from Swahili 
words “ki denga pepo”, which translates “sudden 
cramp like seizure” [2], [6]. The signs and 
symptoms which are suggestive of the disease can 
be traced back as early as 265–420 AD in the 
Chinese Chin Dynasty where it was believed to 
be a type of water poison linked to insects and 
water [2], [6], [7]. An ancient clinical dengue-like 
illness was also recorded in a Chinese medical 
encyclopedia in 992 [8]. However, the first 
reported epidemics of dengue fever occurred in 
1779-1780 in Asia, Africa, and North America 
[7], [9]. In India, the first recorded epidemic of 
clinically dengue-like illness occurred at Madras 
in 1780 and later, DENV was isolated for the first 
time almost simultaneously in Japan and Calcutta 
in 1943–1944 [8], [10]. 
2.1 Dengue in the Asian region 
The major occurrence of events during the 
expansion of Dengue in Asia is summarized in 
Figure 1 below. Dengue illness was first 
virologically proved to be a dengue fever 
epidemic in  around 1963 along the East Coast of 
India where it had spread throughout the country 
causing the first full-blown epidemic of dengue 
hemorrhagic fever/dengue shock syndrome in 
North India in 1996 [8]. 
Whereas dengue had been eradicated from China 
for about 32 years, the 1978 epidemic and several 
other localized epidemics in the 1980s attributed 
to Aedes aegypti vector in coastal areas and Aedes 
albopictus vector in inland regions, suggested that 
the reemergence of dengue in China resulted 
from the introduction of the infection by 
travelers and refugees from areas of Asia where 
dengue is endemic [9]. 
2.2 Dengue in the African Region 
Epidemic dengue fever caused by all four 
serotypes started increasing dramatically in Africa 
in 1980s, particularly in the parts of Kenya, 
Somalia and Mozambique, with epidemics most 
attributed to DENV-2 & 3 [2], [12]. Dengue 
epidemics caused by DENV-1 & 2, have also 
long been reported in parts of West Africa 
(particularly Nigeria) although there is scanty 
information on DHF because of its overlap in 
clinical symptoms with Dengue fever [13], [14]. 
Sporadic cases clinically compatible with DHF 
have also been reported from Mozambique and 
Djibouti [12]. Dengue outbreaks and epidemics 
have been reported in all regions of Africa, and it 
is believed that all four DENV serotypes are in 
circulation although available data suggests that it 
is endemic to 34 African countries [15]. 
Current dengue prevention strategies in Africa 
focus on vector control, although the primary 
aim of such efforts is typically the prevention of 
malaria. Further research is needed to 
characterize the epidemiology of dengue in Africa 
and to better understand the factors involved in 
differences in vulnerability to dengue across 
Africa [15]
 
A global pandemic of dengue begun in Southeast Asia after World War II (1945)
By 1975, DHF had become the leading cause of hospitalization in Southeast Asia (Singapore) and the Pacific . 
Major epidemics were reported for the first time in the Seychelles in 1977
In 1980s, Sri Lanka, India, Taiwan, Maldive Islands and the People’s Republic of China reported their first major 
DHF epidemics
The People’s Republic of China had a series of epidemics caused by all four serotypes, and its first major 
epidemic of DHF, caused by DENV-2, was reported on Hainan Island (1985)
Singapore started having a resurgence of dengue DHF in 1990
Pakistan and Saudi Arabia reported the first epidemic of dengue fever (DENV-2), by 1994
Figure 1: Summary of the expansion of dengue in Asia [2], [7], [11], [12] 
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2.3 Dengue in the American region 
The emergence of Dengue as a major public 
health problem has been most dramatic in the 
American region since when, an effort to prevent 
urban yellow fever by the Pan American Health 
Organization eradicated Aedes aegypti from most 
Central and South American countries in the 
1950s and 1960s leading to only a few sporadic 
cases of epidemic Dengue in the region, 
concealed much on the Caribbean Islands [12]. 
Major epidemics caused by DENV-1 & 4 were 
reported throughout the region over a 16-year 
period since 1977 although DENV-2 & 3 had 
focal distributions in Colombia and Puerto Rico 
[11], [12], [16]. DENV-4 was detected during a 
dengue outbreak in the Amazonian city of Boa 
Vista in 2010, a time when Brazil was already 
endemic for DENV-1, DENV-2 and DENV-3 
[17]. The near simultaneous occurrence of 
outbreaks on three continents indicates that these 
viruses and their mosquito vectors have had a 
worldwide distribution in the tropics for more 
than 200 years [3], [7], [9].  
3 Dengue Transmission 
Dengue viruses, unlike most arboviruses, they 
rely on transmission by mosquito vectors that live 
in close association with people. The humans 
serve as reservoir and amplification hosts since 
most DENVs that cause human diseases are not 
zoonoses [18]. The greatest health risk of 
arboviral emergence is driven by extensive 
tropical urbanization and its colonization by the 
highly anthropophilic mosquito, Aedes (Stegomyia) 
aegypti [1], [18]. Aedes aegypti is the principal vector 
of Dengue fever [19]. The recent invasion into 
the Americas, Europe and Africa by Aedes 
(Stegomyia) albopictus, a secondary vector of 
DENV has enhanced urban transmission of 
these DENVs into tropical as well as temperate 
regions [18], [19]. DENV-3 has also been 
detected in other mosquito vectors like the 
Mansonia africana  in Nigeria [20]. Even though 
Aedes albopictus is highly anthropophilic, it is more 
dependent on vegetation and associated 
resources associated with it thus more common 
in suburban and rural areas [21]. The expansion 
of Dengue has been attributed to the role of 
human transportation [22]. It should be noted 
that both Aedes aegypti and Aedes albopictus are 
aggressive daytime biters and container-
inhabiting species that lay eggs in clean water-
containing receptacles in and around the home 
environment [21], [23]. They can also bite at night 
if there is sufficient artificial lighting. Aedes aegypti 
usually bites at the ankles of humans whereas 
Aedes albopictus biting peaks during early morning 
or late afternoon [23]. 
4 Dengue Reemergence 
There are complex reasons for the dramatic 
reemergence of Dengue as a major global health 
problem although, Gubler and Clark, (2008) 
identified some features as summarized in Table 
1 below. 
Table 1: Summary of the key factors that have led 
contributed to Dengue reemergence [5], [12]. 
  
The inadequate capacity of effective mosquito 
control strategies in most dengue-endemic 
countries is the greatest challenge facing the 
world today since most adult mosquito control 
still relies on ultra-low-volume insecticide space 
sprays which are relatively ineffective in 
controlling Aedes mosquitoes. In addition, the so 
called “competing priorities” or the “crisis 
mentality” which emphasizes the implementation 
of “emergency control methods” in response to 
Competing priorities or the so called “crisis mentality” within 
the global health system
Deteriorated public health infrastructure in low and middle 
income countries makes it difficult to control dengue 
epidemics
Paucity of mosquito control programs in areas where Dengue 
fever has been eradicated
Globalization by air transport and increases worldwide trade 
in second hand tyres has facilitated the breeding and 
movement of Dengue vectors
Uncontrolled urban expansion associated with the concurrent 
population growth have created a favourable environment for 
the breeding of Aedes aegypti and Aedes albopictus vectors
The inadequate capacity of most countries to implement 
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epidemics rather than on developing programs to 
prevent epidemic transmission has allowed 
dengue epidemics to reach or passed the peak of 
transmission before it is detected [12]. 
4.1 Community Involvement and Social 
Perspectives: A Challenge 
The stages of dengue transmission present 
several possibilities for behavioural intervention, 
through horizontal or vertical programmes, or a 
combination of the two, but each of these actions 
has different implications for the reach, adoption, 
effect and maintenance of the programme and, 
may vary according to the specific areas of 
application [24]. Elder and Ballenger-Browning, 
(2009) reviewed some of the key features that 
must be addressed by mosquito control and 
dengue control programmes to be deemed 
successful and they are summarized in the Figure 
2 below. But unlike malaria, there is limited 
knowledge on social aspects of DENV 
epidemiology, such as understanding the degree 
up to which human mobility and social 
interactions affect exposure and transmission of 
DENV, and the human behavioral changes that 
need to occur to render a community-based 
intervention more effective and sustainable [3], 
[25]. Clearly, this is an area where 
multidisciplinary research is needed to fill 
important knowledge gaps [3]. 
Figure 2: Important scientific questions that deem 
a dengue control programme successful [24], [25]. 
The extensive implementation of standard 
control actions recommended by a control 
programmes for example in Brazil, shown to 
have only a slight decrease in mosquito density 
therefore, it is recommended that Dengue 
control programmes should work hand in hand 
with public consultation/engagement, 
behavioural change, intermittent information 
campaigns and actions that go beyond technical 
impositions for these programmes to be effective 
[17]. The increase of Dengue/DHF worldwide is 
everyone’s responsibility therefore, increasing 
awareness of improved water storage practices 
among affected populations could drastically 
reduce the density of Aedes adult mosquitoes 
hence reducing transmission [25], [26]. Proper 
knowledge and information regarding dengue 
practices should be emphasized in dengue 
endemic regions [25], [27]. 
4.2 Dengue Surveillance Systems: A 
Challenge 
The implementation of timely and effective 
mosquito control strategies is highly dependent 
on data generated by surveillance systems. The 
increasing levels of globalization has put travelers 
at a high risk of acquiring dengue infection and 
hence its spread to non-endemic regions 
however, these very travelers serve as sentinels to 
alert the international community of any dengue 
epidemics [28], [29]. This is done through a global 
surveillance network called the ‘GeoSentinel’ that 
monitors all travel-related illnesses [28]. As of 
2012, the GeoSentinel estimated that dengue 
accounts for 2% of all illnesses among travelers 
from dengue-endemic regions and was the most 
frequent cause of febrile illness in travelers 
returning from Southeast Asia [28]. Using this 
kind of estimation is however dangerous since it 
varies according to the reporting requirements of 
a particular country and much affected by the 
non-specific clinical presentation of the disease 
[22], [29]. In Nigeria for example, relying on 
clinical diagnosis may not clearly reflect the actual 
dengue risk as a lot of cases go undetected [14]. 
Emphasizing routine diagnosis can enhance 
dengue virus surveillance and consequently 
improve patient care in West Africa. Dengue 
surveillance has also relied on the larval surveys 
Is it effective under ideal conditions?
Does it have a confirmed effect on 
human behaviour related to control of the 
vector?
Can it be maintained over a sufficiently 
long time? 
Can it reach a large proportion of an 
extensive audience?
Can it be adopted by most of the community?
136 
 
 ISSN: 2456-7132  
Available online at Journals.aijr.in 
Amos Watentena et al., Int. Ann. Sci.; Vol. 9, Issue 1, pp:132-140, 2020 
and other methods monitoring the productivity 
of breeding containers of Dengue vectors [3]. 
Assessing the actual risk of human infection by 
DENV based on immature Aedes mosquito 
indices has proven difficult and it requires 
validation. Therefore, researchers have rather 
suggested the use of appropriate spatial scale of 
assessing the entomological risk by individual 
households involving the determination of 
relative abundance of adult vectors in relation to 
human serotype-specific herd immunity, 
climate/weather, introduction of unique viruses 
and mosquito-human contact [30], [31]. Also, 
integrating the recently developed multi-
platforms application in Dengue entomological 
surveillance system should be emphasized across 
the globe to cost-effectively support the 
entomological unit in fieldwork during 
surveillance missions [32]. 
4.3 Challenges with Dengue Vector 
Control 
The effective and sustainable control of mosquito 
vectors is a puzzling global health challenge yet 
vector control is the most widespread tool to 
curb dengue epidemics. The proven vector 
control tools recommended by the World Health 
Organization Vector Control Advisory Group 
for use in vector control programs are insufficient 
to meet the growing challenge of Dengue 
epidemics therefore, additional measures like the 
use of vaccines and antivirals are required [33]. 
The most widely adopted strategy to minimize 
Dengue fever has been the control of the Aedes 
mosquito larvae populations however, the 
emergence of insecticide resistance has amplified 
the interest in finding natural products effective 
against larval/adult Aedes aegypti and Aedes 
albopictus densities. Plant-derived compounds 
(botanicals and essential oils) have been 
recommended in vector control because they are 
safer and have lower toxicity to humans as 
compared to conventional insecticides [22], [33]–
[35]. Also, due to strong conspecific egg-laying 
behavior of Aedes aegypti and Aedes albopictus 
populations, combining larviciding with 
strategies that kill mosquitoes in later stages 
(pupae) of their development like the insect 
growth regulators, will enhance vector control a 
phenomenon called ‘density-dependent larval 
competition and late acting insecticide’ [31], [36], 
[37]. Research on other methods like; the use of 
local gene drives, the bacterium, the eave tubes, 
mosquito lures, attractive toxic sugar baits 
(ATSBs) and night vision, has almost been 
completed but their application has been on a 
small scale [38]–[41]. Wolbachia has shown to be 
an efficient novel biological control agent though 
transgenics still face ethical concerns [40], [42]. 
As scientists resort to the use genetically modified 
mosquitoes, the major challenge to overcome is 
the development of efficient genetic drive 
systems that spread effector genes into local 
vector populations [39]. Ecological models 
illustrating the role of mosquito control and 
awareness parameters on the Dengue threshold 
clearly outline the important role of vector 
control in disease prevention [43], [44]. Such 
models can be used to guide stakeholders in the 
application of pre-emptive dengue vector control 
thereby enhancing disease management [45]. 
Support from the government, public health 
organizations, donors, community engagement 
and stakeholders is critical in the development of 
sustainable DENV control programs [46]. 
4.4 The Challenge with Diagnostic 
Methodologies 
Timely, efficient and accurate diagnosis of 
Dengue is of primary importance for outbreak 
control, pathogenesis, academic research, vaccine 
development, surveillance activities, clinical trials 
and clinical care [47]. Clinical care involves early 
detection of dengue infection, case confirmation 
and differential diagnosis with other infectious 
diseases. The most commonly used diagnostic 
techniques include: virus in cell culture, viral 
nucleic acid (molecular methods), dengue virus 
antigens/specific antibodies (serological tests) 
and hematological test (platelet and hematocrit 
value) [47]. For early stages, virus isolation, 
genome detection or antigen identification may 
each be used for diagnosis verses serology at 
acute phase. Using a combination of two or more 
of these techniques increases the accuracy of 
diagnosis. Whereas progress had been made in 
development of commercial test kits which claim 
rapid detection of anti‑dengue IgM and IgG 
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antibodies, most of them have been questioned 
or unknown because proper validation studies 
have not been performed and the results not yet 
publicly declared [47]. The NS1 antigen assay 
(serological diagnosis) and ELISA are the best 
new alternatives for antibody diagnosis due to 
their high degrees of specificity and sensitivity 
[47]. However, the clinical diagnosis in the 
absence of laboratory confirmation is often 
unreliable but the cross-sectional serologic 
surveys have the potential to shed light on the 
broader population burden of DENV without 
these biases though the serologic cross-reactions 
among antibody-based assays for Flaviviruses can 
limit the reliability of such studies in the absence 
of confirmatory testing [48]. Further studies 
should investigate the specificity and sensitivity 
of promising novel technologies. 
4.5 Global Health System: The 
Unresolved Hurdle 
Later in 2015, The Lancet showed how the 
India’s health system was overrun with just 
21,000 dengue cases, the worst outbreak in the 
previous 5 years by then. The country’s national 
media showed state hospitals full of patients, with 
some sharing beds, and private hospitals refusing 
to provide care [49]. India’s response to such 
acute public health emergency demonstrates the 
inadequate capacity of most dengue endemic 
countries (like Thailand, Cambodia, Bangladesh 
and Nigeria) in handling outbreaks and points to 
a healthcare system that is chronically 
underfunded, unregulated, and has inadequate 
infrastructure [49]. A similar study has confirmed 
a high societal and individual family burden of 
dengue in Cambodia [50].The emergence and 
reemergence of other viruses like filoviruses 
(Ebola) and coronaviruses (Covid-19) has 
strongly made the situation worse [51]. This is 
most likely to overturn all the efforts which had 
been put in place controlling Dengue and 
increases competition for the healthcare. 
4.6 The Challenge with Drug Discovery 
The development of small molecule DENV 
inhibitors as a tool to prevent/treat Dengue faces 
major hurdles in combining pan-serotypic 
efficacy, safety, and optimal drug-like properties 
[33]. Marques and Kaplan, (2015) proposed a 
dengue antiviral target product that could address 
some of these challenges although they predicted 
that financial return of some of these dengue 
drug discovery projects may not compensate for 
the initial investment in research and 
development. The successful translation from 
basic knowledge into effective DENV control 
interventions ultimately depend on the active 
collaboration and communication between 
researchers from different disciplines and on the 
economic support from funding agencies and 
institutions [3].  
4.7 Challenges with the Development of 
Vaccines 
There is now a better understanding of the 
fascinating complexities in DENV infection and 
transmission than before and this is beginning to 
yield novel and more effective control tools. 
Research breakthroughs over the past 20 years 
have yielded vaccines and myriad of a candidate 
vaccines although mosquito vector control 
remains the only and most effective mode of 
preventing human dengue infection [3], [4], [8]. 
By 2018, the first dengue vaccine, CYD-
tetravalent dengue vaccine (CYD-TDV) or 
Dengvaxia (Sanofi Pasteur, Lyon, France) was 
licensed in 20 countries including Mexico and 
Brazil though initial findings from large scale 
clinical trials shown good but incomplete 
protection against severe dengue [52]–[55]. CYD-
TDV is a live recombinant tetravalent dengue 
vaccine given as a 3-dose series on a 0, 6 and 12 
month schedule [53], [56]. Whereas progress is 
being made in the production of vaccines; the 
lack of an animal model that reproduces the 
disease observed in humans, the necessity of the 
vaccine to be effective against all 4 DENV 
serotypes, and the lack of an identified correlate 
of protection, are undermining the complexities 
of vaccine development [4], [57]–[59]. To address 
some of these challenges, humans are being used 
in preclinical trials which is ethically dangerous 
and has been underpinned by the non-existence 
of a licensed anti-dengue therapeutic agent that 
could treat a volunteer who becomes ill following 
challenge especially with non-protective wild-
type DENV vaccination [57], [58]. In addition, 
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Many new antiviral compounds against the NS5 
protein of DENV are being investigated for 
example; the phosphoamidate nucleoside pro-
drug GS5734 also called “Remdesivir” (that is 
active against Ebola virus, arenaviruses, and 
coronaviruses) and “Favipiravir,” as broad-
spectrum antivirals [51]. They are starting to 
show promising results. Predictive models have 
shown that weakly efficacious vaccination 
strategies against multiple virus serotype diversity 
can be counter-productive to disease control 
efforts [55], [60]. 
4.8 Tailoring Dengue interventions in 
the COVID-19 response: A Challenge 
The rapid emergence and spread of COVID-19 
across the world has created massive global 
disruptions that are impacting lives and 
undermining the global efforts to prevent 
Dengue [61]. Whereas there is remarkable work 
being done to address this challenge [61], it is 
essential not to ignore other killer diseases like 
malaria and Dengue/DHF. The COVID-19 
pandemic could be devastating on its own but its 
effects can be substantially further amplified if 
the response undermines the provision of life-
saving services for other diseases [61], [62]. In this 
regard therefore, Ministries of Health and 
Dengue control programmes must ensure that 
Dengue control efforts are not hampered or 
neglected as they tackle the COVID-19 
pandemic. The Pan-American Organization for 
Health reported about 560,000 new infections 
and 118 deaths of Dengue fever for the first two 
months of 2020 [62]. According to Laura Lopez 
in an interview with DW TV [62], the 
containment of DENV could work with a change 
in the behaviour of the population and proper 
direction of resources amidst COVID-19.  
5 Conclusion 
The recent reemergence of Dengue and the 
global expansion of Dengue vectors presents a 
serious global health challenge. At a time when 
the world is struggling with a pandemic, Dengue 
control may require a smart, complex and 
multifaceted approach outlining proper resource 
allocation towards prevention/control strategies, 
evidence-based clinical care, and mass 
vaccination in endemic regions, for a certain level 
of eradication or containment to be achieved. 
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